Olivia

Study evaluating the safety and efficacy of gemlapodect (NOE-105) in adults with Childhood Onset Fluency Disorder (also known as stuttering) Top-line data expected in Q4 2023 BASEL, Switzerland / Boston, MA, August 4, – Noema Pharma, a clinical-stage biotech company targeting debilitating central nervous system (CNS) indications, today announced the dosing of the first patient […]

BASEL, Switzerland, May 6, 2022 – Noema Pharma, a Swiss clinical-stage Biotech company targeting debilitating central nervous system (CNS) indications, today announces Luigi Costa, Chief Executive Officer, and Michael Gutch, Chief Financial Officer, will attend and present at two upcoming investor events: BioEquity Europe, Milan, Italy and virtually, May 16-18, 2022 Presentation on Tuesday 17 May

BASEL, Switzerland, February 22, 2022 – Noema Pharma, a Swiss-based clinical stage company targeting orphan central nervous system (CNS) diseases, today announces the appointment of Michael Gutch, Ph.D., as Chief Financial Officer. Dr. Gutch has extensive experience in the healthcare and pharmaceutical industries and venture capital investment. He served as Executive Director of Corporate Development

Study evaluating the efficacy of NOE-101 for management of pain associated with trigeminal neuralgia BASEL, Switzerland, February 22, 2022 – Noema Pharma, a Swiss-based clinical stage company targeting orphan central nervous system diseases, today announces the dosing of its first patient in its Phase 2b clinical trial of the mGluR5 inihibitor NOE-101 in trigeminal neuralgia

Study to evaluate efficacy of NOE-101 for management of pain associated with trigeminal neuralgia BASEL, Switzerland, February 14, 2022 – Noema Pharma, a Swiss-based clinical stage company targeting orphan central nervous system (CNS) diseases, today announces the U.S. Food and Drug Administration (FDA) has authorized an Investigational New Drug (IND) application to initiate a Phase

BASEL, Switzerland, October 4, 2021 –Noema Pharma AG, a Swiss-based clinical stage company targeting orphan central nervous system (CNS) diseases, today announces the appointment of Jeffrey Jonas MD as Chairman of the Board of Directors. Dr. Jonas is a neuropsychiatry expert, former Chief Executive Officer and current Chief Innovation Officer of Sage Therapeutics, with more

BASEL, Switzerland, September 2, 2021 – Noema Pharma, a Swiss-based clinical stage company targeting orphan central nervous system (CNS) diseases, today announces it will attend two upcoming investor events: Swiss Biotech Day, in-person in Basel, September 6, 2021 Luigi Costa will meet with investors in one-on-one meetings The UBS Biotech Private Company Symposium, virtual, September